Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall
Annemarie Bell, VP, Chief HR Officer at Standex International (NASDAQ:SXI), sold 1,184 shares of common stock on September 3, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a price of $202.12, for a total transaction value of $239,310. The sale comes as SXI trades near its 52-week high of $212.66, with the stock delivering a robust 17.81% return over the past year. According to InvestingPro, the company has maintained dividend payments for 55 consecutive years, demonstrating strong financial stability. For deeper insights into insider trading patterns and 8 additional key ProTips, investors can access the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Standex International Corporation reported strong financial results for the fourth quarter of 2025, surpassing market expectations. The company posted an earnings per share (EPS) of $2.28, outperforming the forecasted $2.10, which marked an 8.57% surprise. Revenue also exceeded projections, coming in at $222 million compared to the anticipated $214.44 million. Following these results, DA Davidson raised its price target for Standex International to $219, maintaining a Buy rating. The firm highlighted the potential for Standex to reverse its nearly two-year streak of quarterly organic revenue declines. Similarly, Roth/MKM increased its price target to $205, also maintaining a Buy rating, citing strong sales and adjusted EBITDA results. Standex achieved a 23% year-over-year sales growth and expanded its adjusted EBITDA margins by 350 basis points. These developments reflect positive analyst sentiment and suggest a favorable outlook for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.